Treatment of pancreatic ductal adenocarcinoma (PDAC) is increasingly multidisciplinary, with neoadjuvant strategies (chemotherapy, radiation, and surgery) administered in patients with resectable, borderline resectable, or locally advanced disease. The rational supporting this management is the achievement of both higher margin-negative resections and conversion rates into potentially resectable disease and in vivo assessment of novel therapeutics. International guidelines suggest an initial staging of the disease followed by a multidisciplinary approach, even considering the lack of a treatment approach to be considered as standard in this setting. This review will focus on both literature data supporting these guidelines and on new opportunities related to current more active chemotherapy regimens. An analysis of the pathological assessment of response to therapy and the potential role of target therapies and translational biomarkers and ongoing clinical trials of significance will be discussed.

Neoadjuvant multimodal treatment of pancreatic ductal adenocarcinoma / Silvestris, Nicola; Longo, Vito; Cellini, Francesco; Reni, Michele; Bittoni, Alessandro; Cataldo, Ivana; Partelli, Stefano; Falconi, Massimo; Scarpa, Aldo; Brunetti, Oronzo; Lorusso, Vito; Santini, Daniele; Morganti, Alessio; Valentini, Vincenzo; Cascinu, Stefano. - In: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. - ISSN 1040-8428. - 98:(2016), pp. 309-324. [10.1016/j.critrevonc.2015.11.016]

Neoadjuvant multimodal treatment of pancreatic ductal adenocarcinoma

CASCINU, Stefano
2016

Abstract

Treatment of pancreatic ductal adenocarcinoma (PDAC) is increasingly multidisciplinary, with neoadjuvant strategies (chemotherapy, radiation, and surgery) administered in patients with resectable, borderline resectable, or locally advanced disease. The rational supporting this management is the achievement of both higher margin-negative resections and conversion rates into potentially resectable disease and in vivo assessment of novel therapeutics. International guidelines suggest an initial staging of the disease followed by a multidisciplinary approach, even considering the lack of a treatment approach to be considered as standard in this setting. This review will focus on both literature data supporting these guidelines and on new opportunities related to current more active chemotherapy regimens. An analysis of the pathological assessment of response to therapy and the potential role of target therapies and translational biomarkers and ongoing clinical trials of significance will be discussed.
2016
98
309
324
Neoadjuvant multimodal treatment of pancreatic ductal adenocarcinoma / Silvestris, Nicola; Longo, Vito; Cellini, Francesco; Reni, Michele; Bittoni, Alessandro; Cataldo, Ivana; Partelli, Stefano; Falconi, Massimo; Scarpa, Aldo; Brunetti, Oronzo; Lorusso, Vito; Santini, Daniele; Morganti, Alessio; Valentini, Vincenzo; Cascinu, Stefano. - In: CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. - ISSN 1040-8428. - 98:(2016), pp. 309-324. [10.1016/j.critrevonc.2015.11.016]
Silvestris, Nicola; Longo, Vito; Cellini, Francesco; Reni, Michele; Bittoni, Alessandro; Cataldo, Ivana; Partelli, Stefano; Falconi, Massimo; Scarpa, Aldo; Brunetti, Oronzo; Lorusso, Vito; Santini, Daniele; Morganti, Alessio; Valentini, Vincenzo; Cascinu, Stefano
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S1040842815300834-main.pdf

Accesso riservato

Tipologia: Versione pubblicata dall'editore
Dimensione 847.73 kB
Formato Adobe PDF
847.73 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1108487
Citazioni
  • ???jsp.display-item.citation.pmc??? 17
  • Scopus 35
  • ???jsp.display-item.citation.isi??? 35
social impact